<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628667</url>
  </required_header>
  <id_info>
    <org_study_id>SH-NEE-0002</org_study_id>
    <secondary_id>D9611C00002</secondary_id>
    <nct_id>NCT00628667</nct_id>
  </id_info>
  <brief_title>Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux</brief_title>
  <official_title>A Multicenter, Double -Blind, Placebo-controlled Study to Evaluate the Effects of Esomeprazole 40mg Bid on the Signs and Symptoms of Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study looks at how effective acid suppression therapy is on symptoms associated with
      chronic posterior laryngitis (CPL) in patients with documented pharyngeal acid reflux.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily diary cards and investigator symptom assessment to evaluate the efficacy of acid suppression therapy on symptoms associated with chronic posterior laryngitis (CPL) in patients without documented pharyngeal acid</measure>
    <time_frame>Dialy diary cards, investigator assessments, laryngoscopy at week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily diary cards and investigator symptom assessment throughout to evaluate the efficacy of acid suppression therapy on resolution of signs of CPL at weeks 8 and 16 in patients without documented pharyngeal acid reflux.</measure>
    <time_frame>Dialy diary cards, investigator assessments, laryngoscopy at weeks 8 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaire</measure>
    <time_frame>Quality of life questionnaire completed at screening and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability by collecting an ongoing record of adverse events.</measure>
    <time_frame>Ongoing to week 16.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Posterior Laryngitis (CPL)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>40mg orally twice daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One or more of the following symptoms present for at least 3 consecutive months:
             throat clearing, cough, globus, sore throat, or hoarseness.

          -  Patients must complete a run-in diary card, and this will be looked at to ensure met
             the inclusion criteria.

          -  Must have a total score of 5 or more on the Chronic Posterior Laryngitis Index (CPLI)
             grading system.

        Exclusion Criteria:

          -  A number of diseases / conditions would preclude a patient from taking part in the
             study, as listed in the protocol.

          -  If the patient is on certain medications this will also preclude them from taking
             part.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Fernstrom</last_name>
    <role>Study Director</role>
    <affiliation>Nexium Global Product Director, AstraZeneca</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tore Lind, MD - Nexium Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Chronic Posterior Laryngitis</keyword>
  <keyword>CPL</keyword>
  <keyword>Pharyngeal acid reflux</keyword>
  <keyword>Esomeprazole</keyword>
  <keyword>Nexium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
    <mesh_term>Laryngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

